Drugs / Hyperpolarized 129-Xenon gas
Hyperpolarized 129-Xenon gas
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT02478268 Comparator | May 2015 → Sep 2020 | idiopathic pulmonary fibrosis | Bastiaan Driehuys | Completed | No outcome recorded |
| Phase 2 | NCT02478255 Comparator | Mar 2016 → Jan 2022 | radiation-induced disorder | Bastiaan Driehuys | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hyperpolarized 129-Xenon gas | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02478255 ↗ |
| Modality | Diagnostic / imaging agent | “magnetic resonance imaging (MRI) using inhaled hyper polarized xenon-129 (129Xe) gas” NCT02478255 ↗ |
| Route | Inhaled | “inhaled hyper polarized xenon-129 (129Xe) gas” NCT02478255 ↗ |